The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation

Tarighat, S S, Santhanam, R, Frankhouser, D, Radomska, H S, Lai, H, Anghelina, M, Wang, H, Huang, X, Alinari, L, Walker, A, Caligiuri, M A, Croce, C M, Li, L, Garzon, R, Li, C, Baiocchi, R A, Marcucci, G·2016·Leukemia
DOI 10.1038/leu.2015.308

Cited by (171)

Items 101–171 of 171

  1. TAF1 inhibitor Bay-299 induces cell death in acute myeloid leukemia
    Lixin Zhou, Qi Yao, Le Ma, Hui Li, Jieping Chen · 2021 · Translational Cancer Research
  2. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
    Fiona Brown-Burke, Inah Hwang, Shelby L. Sloan, Claire Hinterschied, JoBeth Helmig-Mason, Mackenzie Long, Wing Keung Chan, Alexander Prouty, Ji-Hyun Chung, Yang Zhang et al. · 2023 · Blood Advances
  3. Cell metabolic profiling of colorectal cancer via 1H NMR
    Suyin Ge, Qingqing Zhang, Yizhen Tian, Luyang Hao, Jingru Duan, Baolai Zhang · 2020 · Clinica Chimica Acta
  4. circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation
    Xinyu Yang, Jinting Liu, Wancheng Liu, Hanyang Wu, Yihong Wei, Xiaodong Guo, Hexiao Jia, Can Can, Dongmei Wang, Xiang Hu et al. · 2024 · Leukemia
  5. FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms
    Caroline P. Poubel, Marcela Braga Mansur, Mariana Boroni, Mariana Emerenciano · 2019 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  6. Therapeutic targeting of chromatin alterations in leukemia and solid tumors
    Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna M. Thomas, Michael W.M. Kühn, Michael Lübbert · 2025 · International Journal of Cancer
  7. An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4- mediated ferritinophagy as a dependence in Tet2 -deficient hematopoiesis
    Justin Ching Ting Loke, Peter Geon Kim, Thuy T. P. Nguyen, Meaghan Boileau, Marie E. McConkey, Aidan Miller, Wesley Shin, Christopher A. Hergott, Maria Ericsson, Anja E. H. Nordstrom et al. · 2025 · Blood
  8. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
    Michael W.M. Kühn, Naveen Pemmaraju, Florian Heinrich Heidel · 2025 · Leukemia
  9. Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy
    Michael Maher, Jeannine Diesch, Marguerite-Marie Le Pannérer, Marcus Buschbeck · 2021 · Cancers
  10. PRMTs and miRNAs: functional cooperation in cancer and beyond
    Jiamin Jin, Matthew Martin, Antja-Voy Hartley, Tao Lu · 2019 · Cell Cycle
  11. Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine
    Li‐Juan Tang, Guokang Sun, Ting‐juan Zhang, Dehong Wu, Jing‐dong Zhou, Bei-bei Ma, Zi‐jun Xu, Xiang-mei Wen, Qin Chen, Dong‐ming Yao et al. · 2019 · Cancer Cell International
  12. In silico approach of novel HPPD/PDS dual target inhibitors by pharmacophore, AILDE and molecular docking
    Juan Shi, Hai‐Feng Cao, Chao‐Fan Wang, Shuang Gao, Jia-Yu Wang, Lixia Zhao, Fei Ye, Ying Fu · 2023 · Journal of the Taiwan Institute of Chemical Engineers
  13. SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression
    Zhenyu Zhou, Zheng Chen, Qianlei Zhou, Shiyu Meng, Juanyi Shi, Sintim Mui, Hai Jiang, Jianhong Lin, Gui He, Wenbin Li et al. · 2024 · Cancer Science
  14. Targeting PRMT5 in cancer: Mechanistic insights and clinical progress
    Joohyun Lee, Jiye Kim, Inah Hwang · 2025 · Biomedicine & Pharmacotherapy
  15. Inflammation in cancer cachexia: still the central tenet or just another player?
    Noemi Iaia, Chiara Noviello, Maurizio Muscaritoli, Paola Costelli · 2025 · American Journal of Physiology-Cell Physiology
  16. Mechanisms of Histone Modifications
    Ludovica Vanzan, Athéna Sklias, Zdenko Herceg, Rabih Murr · 2017 · Elsevier eBooks
  17. Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias
    Francesca Pirini, Anna Ferrari, Mouna Jandoubi, Irene Azzali, Davide Angeli, Rossana Mondrone, Chiara Bracci, Francesca Ruggieri, Giovanni Martinelli, Giorgia Simonetti · 2025 · Cell Death Discovery
  18. Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities
    Yoonae Jeong, Yena Cho, Yong Kee Kim · 2026 · Journal of Biomedical Science
  19. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer
    Chaohua Guo, Lintao Wu, Xumei Zheng, Lin Zhao, Xiaojia Hou, Zhijun Wang, Chun Han · 2023 · Current Topics in Medicinal Chemistry
  20. Aberrant miRNA expression and protein arginine methyltransferase 5 (PRMT5) in cancer: A review
    Saı̈d Sif, Majdi Al-Alawneh · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  21. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
    Shelby L. Sloan, Kyle A. Renaldo, Mackenzie Long, Ji-Hyun Chung, Lindsay E. Courtney, Konstantin Shilo, Youssef Youssef, Sarah Y. Schlotter, Fiona Brown-Burke, Brett G. Klamer et al. · 2021 · PLoS ONE
  22. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα
    Xinping Huang, Yongfeng Yang, Dan Zhu, Yan Zhao, Min Wei, Ke Li, Hong‐Hu Zhu, Xiaofeng Zheng · 2022 · Cellular and Molecular Life Sciences
  23. The Role of Chromatin-Associated Proteins in Cancer
    Kristian Helin, Saverio Minucci · 2016 · Annual Review of Cancer Biology
  24. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2low Adult T-Cell Leukemia/Lymphoma
    Tomonaga Ichikawa, Akira Suekane, Shingo Nakahata, Hidekatsu Iha, Kazuya Shimoda, Takashi Murakami, Kazuhiro Morishita · 2024 · International Journal of Molecular Sciences
  25. PRMT5: A Promising Synthetical Lethal Target for MTAP-Deleted Cancers
    Bang Li, Jin-Qi Yu, Zhenjiao Yang, Yuanxiang Wang · 2025 · Journal of Medicinal Chemistry
  26. The role of protein arginine methyltransferases in kidney diseases
    Chunyun Zhang, Shougang Zhuang · 2020 · Clinical Science
  27. Inducement of ER Stress by PAD Inhibitor BB-Cl-Amidine to Effectively Kill AML Cells
    Yanni Sun, Yanni Ma, Xiaoqing Jia, Qi Yao, Jieping Chen, Hui Li · 2022 · Current Medical Science
  28. The role and application of transcriptional repressors in cancer treatment
    Miso Park, Keon Wook Kang, Ji Won Kim · 2023 · Archives of Pharmacal Research
  29. Analysis of the error surface of the XOR network with two hidden nodes
    Len Hamey · 1996
  30. PRMT5-FOXM1 axis activates β-catenin/IL8 signaling to drive angiogenesis of gastric cancer
    Xinyu Liu, Chenxiao Tu, Hongwei Yang, Bowen Tang, Yanwei Ye, Huanan Wang · 2025 · Cellular Signalling
  31. Excessive fatty acids activate PRMT5 / MDM2 /Drosha pathway to regulate miRNA biogenesis and lipid metabolism
    Aijun Hou, Xiaoding Xu, Yu Zhang, Hongxiu He, Yihan Feng, Wenhui Fan, Rongrong Tan, Likun Gong, Jing Chen · 2024 · Liver International
  32. Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
    Johanna Rausch, Evelyn Ullrich, Michael W.M. Kühn · 2023 · Frontiers in Immunology
  33. A novel 3-alkenylindol-2-one derivative selectively inhibits the growth of acute myeloid leukemia via modulation of the MYC-PRMT pathway
    Shuhong Dong, Ruiying Yang, Yingwen Wang, Xingqi Fang, Xiang Han, Meng Gu, Shi‐Wu Chen, Baolai Zhang · 2025 · Biochemical Pharmacology
  34. Targeting the epigenome and tumor heterogeneity: advances in immunotherapy for chemoresistant metastatic colorectal cancer
    Yu J Cao, Narasimha Murthy Beeraka, Sergey K. Efetov, Zheng Liu, Akmalbek A. Otabekov, Basappa Basappa, Wensheng Wang, Dan Ma · 2025 · Frontiers in Immunology
  35. Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors
    Tyler M. Brown, Mengtong Cao, Yujun George Zheng · 2022 · Molecules
  36. Dysregulated YY1/PRMT5 axis promotes the progression and metastasis of laryngeal cancer by targeting Hippo pathway
    Nan Wang, Di Wu, Long Qian, Yue Yan, Xiaoqi Chen, Zheng Zhao, Honghong Yan, Xinrui Zhang, Meilan Xu, Wuguo Deng et al. · 2020 · Journal of Cellular and Molecular Medicine
  37. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations
    Qian Zhang, Lun Zhang, Jia Jin, Yaohua Fan, Xiaoguang Wang, Haofeng Hu, Xiaoqing Ye, Lei Wang, Chenxi Cao, Fei Ye · 2022 · Journal of Molecular Modeling
  38. Dysregulation of arginine methylation in tumorigenesis
    Li Xiao, Yaqiong Song, Weiwei Mu, Xiaoli Hou, Te Ba, Shaoping Ji · 2024 · Frontiers in Molecular Biosciences
  39. Purification and Identification of Natural Inhibitors of Protein Arginine Methyltransferases from Plants
    Zhengxin Wang, Ling Xiong, Quanbo Xiong · 2022 · Molecular and Cellular Biology
  40. The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer
    Pengyu Jing, Nianlin Xie, Ximing Zhu, Haizhou Dang, Zhongping Gu · 2018 · Journal of Thoracic Disease
  41. Alterations of histone modifications in cancer
    Maha Mohamed Saber-Ayad, Wafaa S.H. Ramadan, Raafat El‐Awady · 2023 · Elsevier eBooks
  42. Onametostat, a PfPRMT5 inhibitor, exhibits antimalarial activity to Plasmodium falciparum
    Hui Min, Amuza Byaruhanga Lucky, Jesper J. Madsen, Anongruk Chim-Ong, Xiaolian Li, Liwang Cui, Jun Miao · 2024 · Antimicrobial Agents and Chemotherapy
  43. Drug discovery targeting protein arginine methyltransferase 5 (PRMT5): an update
    Zhouyang Gu, Weijia Kong, Xing Liu, Lang Hu, Yucheng Zhou, Zhenchu Liang, Minyue Zhang, Dongyin Chen, Fei Li, Weilin Chen · 2025 · Bioorganic & Medicinal Chemistry
  44. Novel Drugs Targeting the Epigenome
    Zhuo Chen, Honglin Li · 2017 · Current Pharmacology Reports
  45. The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine
    Qing Yan · 2022 · Methods in molecular biology
  46. PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5/C‐Myc Feedback Loop
    Fan Yang, Ping Song, Zhaofeng Xiao, Renyi Su, Xin Fang, Yichao Wu, Xiao Xu, Kai Wang · 2025 · MedComm
  47. Carcinogenesis and Prognostic Utility of Arginine Methylation-Related Genes in Hepatocellular Cancer
    Waleed M Ali, Weirui Xiao, Henry Hoang, Vincent J. Cali, Andre Kajdacsy‐Balla · 2023 · Current Issues in Molecular Biology
  48. A synergistic interaction between PRMT5 and LSD1 inhibitors in AML
    Nesteene Joy Param, Elisa Arceci, Francesco Fiorentino, Luca Pignata, Denis Torre, Nayeli Gutiérrez, Jia Yi Fong, Pierre-Alexis Vincent Goy, Yuyuan Han, Chiara Lambona et al. · 2026 · Science Advances
  49. 13q12.2 deletions and FLT3 overexpression in acute leukemias
    Caroline P. Poubel, Mariana Boroni, Mariana Emerenciano · 2021 · Blood Advances
  50. PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis
    Fiona Brown-Burke, Rachel Saadey, Hsiaoyin Charlene Mao, Paola Marra, Eric Brooks, Alexa Wandtke, Ian Hout, Sydney Leon, Archisha Sharma, Aneeq Yasin et al. · 2025 · Blood Advances
  51. Cotargeting of Androgen Synthesis and Androgen Receptor Expression as a Novel Treatment for Castration-Resistant Prostate Cancer
    Chang‐Deng Hu, Xuehong Deng, Elena Beketova, Jake L. Owens, Jonathan Malola · 2017
  52. PRMT Inhibitors
    Matthijs J. van Haren, Nathaniel I. Martin · 2019 · Topics in medicinal chemistry
  53. The Polymerase Associated Factor Complex-Protein Arginine Methyltransferase Axis: A Mechanism of Acute Leukemia
    Justin Serio · 2017 · Deep Blue (University of Michigan)
  54. Characterizing the Role of Protein Arginine Methyltransferase 5 in Colon Cancer
    Judy Truong · 2018 · TSpace (University of Toronto)
  55. Identification of PRMT5 Inhibitors with Novel Scaffold Structures through Virtual Screening and Biological Evaluations
    Lun Zhang, Chenxi Cao, Jia Jin, Yaohua Fan, Xiaoguang Wang, Qian Zhang, Haofeng Hu, Xiaoqing Ye, Lei Wang, Fei Ye · 2021 · Research Square
  56. Faculty Opinions recommendation of PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
    Scott A. Ness · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  57. Analysis and synthesis of cellular decision making: modeling epigenetic regulation in cell fate networks and designing a distributed synthetic counter circuit
    Tianchi Chen · 2022 · Digital Repository Service (Northeastern University)
  58. Emerging epigenetic therapies: protein arginine methyltransferase inhibitors
    Hannah Pook, Siim Pauklin · 2023 · Elsevier eBooks
  59. PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?
    Andrej Terzic, David J. Curtis · 2023 · Leukemia Research
  60. RECENT ADVANCES IN TARGETING THE PRMT5/MTA COMPLEX
    Christopher R. Smith, Matthew A. Marx · 2023 · Medicinal chemistry reviews
  61. PRMT5 Inhibition Enhances Therapeutic Efficacy of Cisplatin via Mediating miR‐29b‐3p‐Mcl‐1 Expression in Lung Adenocarcinoma
    Haichao Li, Jiangjiang Fan, Weiwei Shen, Yong Zhang, Ximing Zhu, Pei Li, Zhongping Gu, Pengyu Jing · 2025 · Cell Biology International
  62. PRMT5:MEP50 Are Mediators of Treatment‐Induced Neuroendocrine Differentiation in Prostate Cancer
    Hye Seung Nam, Andrew Michael Asberry, Xuehong Deng, Sheng Liu, Jiaoti Huang, Chang‐Deng Hu, Jun Wan, Michael K. Wendt · 2025 · The Prostate
  63. The role of PRMT5-mediated methylation of steroid receptor in breast Cancer
    Thuy Ha Pham · 2022 · theses.fr (ABES)
  64. CARM1 disrupts interactions between ALIX and its partners through arginine methylation and promotes cytokinetic abscission
    Solène Huard · 2024 · theses.fr (ABES)
  65. PRMT5 imposed a dual repression on DDIT3 transcription to promote the malignancy of hepatocellular carcinoma
    Hao Jiang, Jin-Hua Yan, Wen-Jing Tang, Bin Shen, Shuai Mo, Yang Wang, De-Hua Hu, Zhixiong Dong, Shu-Bing Zhang · 2026 · World Journal of Gastroenterology
  66. Epigenetic alterations in Myeloid Malignancies
    Bruno António Cardoso · 2026 · Advances in experimental medicine and biology
  67. Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer
    Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng · 2026 · Molecular Oncology
  68. BindingDB Entry 50002756: Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    BindingDB · 2020 · UC San Diego
  69. BindingDB Entry 50012961: A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode.
    BindingDB · 2022 · UC San Diego
  70. BindingDB Entry 50021155: Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.
    BindingDB · 2025 · UC San Diego
  71. BindingDB Entry 50019870: Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
    BindingDB · 2024 · UC San Diego